Biotech · Private company
Immune-Onc Therapeutics
Track this companyFree. Adds Immune-Onc Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- IO-108Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- IO-108 + cemiplimab combination therapyPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- IO-108 + pembrolizumab combination therapyPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- IO-202Phase 1 · AML With Monocytic DifferentiationClinicalTrials.gov · fetched Nov 12, 2026
- IO-202Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- IO-202 + pembrolizumab combination therapyPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- IO-202 and AzacitidinePhase 1 · AML With Monocytic DifferentiationClinicalTrials.gov · fetched Nov 12, 2026
- IO-202 and Azacitidine + VenetoclaxPhase 1 · AML With Monocytic DifferentiationClinicalTrials.gov · fetched Nov 12, 2026
- RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor typesPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid TumorsPHASE1 · COMPLETED · started Apr 11, 2022ClinicalTrials.gov NCT05309187 · fetched Nov 12, 2026
- First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid TumorsPHASE1 · COMPLETED · started Sep 30, 2021ClinicalTrials.gov NCT05054348 · fetched Nov 12, 2026
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 1, 2020ClinicalTrials.gov NCT04524871 · fetched Nov 12, 2026
- IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMMLPHASE1 · COMPLETED · started Sep 14, 2020ClinicalTrials.gov NCT04372433 · fetched Nov 12, 2026